Konstantin Dragnev, MD
Enriched profileInterim Director, Dartmouth Cancer Center · Dartmouth-Hitchcock Medical Center
Konstantin Dragnev is Interim Director, Dartmouth Cancer Center at Dartmouth-Hitchcock Medical Center. OpenAlex indexes 284 publications with 6,882 citations (h-index 44); ClinicalTrials.gov lists 11 registered studies with this person as an investigator.
Data verified 21 Oct 2026
Overview
Updated 24 Oct 2026
Konstantin H. Dragnev, MD, is Interim Director, Dartmouth Cancer Center at Dartmouth-Hitchcock Medical Center. The public record shows 284 publications with 6,882 citations (h-index 44), centered on Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Lung Cancer Research Studies. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 3 companies, 3 NIH-funded awards (2014–2026).
- Most recent indexed publication: 2026 · Journal of the National Cancer Institute
- Top research focus: Lung Cancer Treatments and Mutations
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 3 companies
Generated from the cited public record · current as of 24 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 6 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 88.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 24 Oct 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Sponsor: 7 Hills Pharma, LLC
Industry payments
Updated 24 Oct 2026
3 companies reported payments to CMS in program years 2021–2024. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20247 payments
- E.R. Squibb & Sons, L.L.C.Program year20241 payment
- Daiichi Sankyo Inc.Program year20211 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
40.3%Kinase inhibitor40.3%Tagrisso100%Part D<11 patientsMetabolism & gastrointestinal
18.5%Corticosteroid18.5%Prednisone100%Part D≥12 patientsNervous system
15.3%Phenothiazine15.3%Prochlorperazine Maleate100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 24 Oct 2026
3 NIH research awards on record, funded 2014–2026 per NIH RePORTER. The latest:
- NCI National Clinical Trials Network - Network Lead Academic Participating Site (UG1)
Dartmouth-Hitchcock Clinic
FY2026$500,430UG1CA233323 - NCI National Clinical Trials Network - Network Lead Academic Participating Site (UG1)
Dartmouth-Hitchcock Clinic
FY2025$304,902UG1CA233323
Congress activity
Updated 24 Oct 2026
53 congress contributions (2004–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract CT140: Final Results from S2302—PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (RP) versus standard of care (SOC) for participants (pts) previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC)
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 24 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Performance of multiple multi-cancer detection tests using a large independent reference set (Alliance A212102).
Journal of the National Cancer Institute
Article2026 - Biomarker-Driven Personalized Immunoprevention: Toward More Efficient Clinical Trials?
Cancer prevention research (Philadelphia, Pa.)
Article2024 - Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.
Journal of cell science
Article2024 - Primary Prevention and Interception Studies in RAS-Mutated Tumor Models Employing Small Molecules or Vaccines.
Cancer prevention research (Philadelphia, Pa.)
Article2023
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03
- 04
- 05A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancerArticle243 citations2011
Network
Updated 24 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 24 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.dartmouth-health.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.dartmouth-health.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.dartmouth-health.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →providers.dartmouth-health.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →geiselmed.dartmouth.edu ↗
Secondary affiliations
appointments beyond the home institution- Professor of Medicine
Geisel School of Medicine, Dartmouth
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.dartmouth-health.org ↗ - Irene Heinz Given Professor in Pharmacology
Geisel School of Medicine and Dartmouth Health
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.dartmouth-health.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancer.dartmouth.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center